Expanded Lung Cancer Claim For Lilly’s Cyramza Faces US FDA Scrutiny

Oncologic Drugs Advisory Committee will consider whether a statistically significant benefit on progression-free survival, but no survival advantage, is enough to secure a first-line lung cancer indication for ramucirumab.

Lung cancer ( film x-ray of chest PA upright : show pleural effusion at left lung due to lung cancer ) ( 2 type of lung cancer : Non-small cell lung cancer , Small cell carcinoma )
Lilly seeks to move Cyramza's metastatic non-small cell lung cancer indication into the first-line setting. • Source: Shutterstock

Eli Lilly & Co.’s bid to expand Cyramza’s (ramucirumab) metastatic lung cancer indication to the first-line setting is facing pushback from the US Food and Drug Administration over the lack of a survival benefit to date and increased toxicity seen in the pivotal RELAY trial.

On 26 February, the Oncologic Drugs Advisory Committee will review Lilly’s supplemental biologics license application for use of ramucirumab, in...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers